Drug General Information |
Drug ID |
D0U6ZT
|
Former ID |
DNC002573
|
Drug Name |
3-Bromo-7-Nitroindazole
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C7H4BrN3O2
|
InChI |
InChI=1S/C7H4BrN3O2/c8-7-4-2-1-3-5(11(12)13)6(4)9-10-7/h1-3H,(H,9,10)
|
InChIKey |
NFSTZPMYAZRZPC-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
826437, 3153161, 5674219, 7888405, 8007079, 8007092, 11110834, 11113670, 11120304, 11120792, 11121280, 11121567, 11122047, 11362636, 11365198, 11367760, 11370543, 11370544, 11373361, 11375922, 14774073, 17404724, 24278258, 26612743, 26747128, 26751855, 26751856, 29220853, 46507791, 47440018, 47440019, 47662058, 47736239, 48259001, 48259002, 48628407, 50104555, 50104556, 50104557, 50104558, 52824169, 53777267, 57320966, 71822505, 81060425, 85230935, 85787746, 85789452, 88727144, 90341482
|
Target and Pathway |
Target(s) |
Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[2]
|
Nitric-oxide synthase, brain |
Target Info |
Inhibitor |
[2]
|
Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[2]
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cycle
|
KEGG Pathway
|
Arginine and proline metabolism
|
Metabolic pathways
|
Calcium signaling pathway
|
cGMP-PKG signaling pathway
|
HIF-1 signaling pathway
|
Sphingolipid signaling pathway
|
PI3K-Akt signaling pathway
|
VEGF signaling pathway
|
Platelet activation
|
Estrogen signaling pathway
|
Oxytocin signaling pathwayhsa00330:Arginine and proline metabolism
|
Phagosome
|
Circadian entrainment
|
Long-term depression
|
Salivary secretion
|
Alzheimer's disease
|
Amyotrophic lateral sclerosis (ALS)hsa00220:Arginine biosynthesis
|
Peroxisome
|
Salmonella infection
|
Pertussis
|
Leishmaniasis
|
Chagas disease (American trypanosomiasis)
|
Toxoplasmosis
|
Amoebiasis
|
Tuberculosis
|
Pathways in cancer
|
Small cell lung cancer
|
NetPath Pathway
|
Wnt Signaling PathwayNetPath_4:EGFR1 Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
Endothelin signaling pathway
|
Interleukin signaling pathway
|
PI3 kinase pathway
|
VEGF signaling pathwayP06959:CCKR signaling map ST
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
Angiopoietin receptor Tie2-mediated signaling
|
Thromboxane A2 receptor signaling
|
SHP2 signaling
|
VEGFR1 specific signals
|
Signaling events mediated by VEGFR1 and VEGFR2
|
PAR1-mediated thrombin signaling eventsil12_2pathway:IL12-mediated signaling events
|
Alpha9 beta1 integrin signaling events
|
ATF-2 transcription factor network
|
IL23-mediated signaling events
|
Signaling mediated by p38-alpha and p38-beta
|
HIF-1-alpha transcription factor network
|
PathWhiz Pathway
|
Arginine and Proline Metabolism
|
Reactome
|
ROS production in response to bacteria
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
eNOS activation
|
Nitric oxide stimulates guanylate cyclase
|
VEGFR2 mediated vascular permeabilityR-HSA-1222556:ROS production in response to bacteria
|
Nitric oxide stimulates guanylate cyclaseR-HSA-1222556:ROS production in response to bacteria
|
WikiPathways
|
ACE Inhibitor Pathway
|
EGF/EGFR Signaling Pathway
|
Myometrial Relaxation and Contraction Pathways
|
JAK/STAT
|
Corticotropin-releasing hormone
|
AGE/RAGE pathway
|
Endothelin Pathways
|
Leptin signaling pathway
|
Effects of Nitric Oxide
|
Metabolism of nitric oxide
|
AngiogenesisWP727:Monoamine Transport
|
Amyotrophic lateral sclerosis (ALS)
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
Spinal Cord Injury
|
Alzheimers Disease
|
Serotonin Transporter ActivityWP619:Type II interferon signaling (IFNG)
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5113). |
---|
REF 2 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |